Effectiveness of the PLAC® Activity Test has been demonstrated across multiple clinical trials and patient populations.

  • The greater the Lp-PLA2 activity, the greater the risk for fatal and nonfatal CHD events (Figure 1)
  • A PLAC Activity Test result above 225 nmol/min/mL identifies patients at increased risk for CHD events across patient type and population (Figure 2)
  • Absolute risk of CHD events is 2.1 times greater with a positive PLAC Test (Figure 2)
Lp-PLA2 Activity and CHD* Risk3
risk ratio
*Fatal and non-fatal events
Figure 1
Risk for CHD Event Rates By Patient Type4
Increased absolute risk for certain sub-populations
Figure 2

The PLAC Test for Lp-PLA2 Activity has a validated cut point of 225 nmol/min/mL

The PLAC® Activity Test incorporates a validated, easy-to-use cut point of 225 nmol/min/mL.


The PLAC Activity Test provides physicians with additional prognostic information previously unavailable with traditional risk factors.   LEARN MORE


The PLAC Activity Test offers enhanced cardiovascular risk assessment from your laboratory.   LEARN MORE